Zhong Guo Xin Wen Wang·2026-01-07 08:49Group 1 - The core viewpoint is that domestic innovative drugs are increasingly gaining global application, with growing brand influence and trust [1] - Baiyao Tai Biopharmaceutical Co., Ltd. has developed Adalimumab injection, which is set to be approved for sale in the UK by September 2025, marking it as the first domestically approved biosimilar of Adalimumab [1] - Guangzhou Development Zone and Huangpu District have established over 4,800 biopharmaceutical companies, achieving at least one innovative drug approval annually for five consecutive years, ranking fifth in national competitiveness [2] Group 2 - Yipin Hong Pharmaceutical Group has over ten global innovative drug projects in development, including the gout drug AR882, which is expected to complete its Phase III clinical trials by the end of 2025 [2] - Ranstone Medical has received approval for its breast cancer targeted drug Capecitabine companion diagnostic kit in Japan by September 2025, marking a significant milestone in China's precision medicine for breast cancer [2] - Ranstone Medical has established partnerships with over 140 innovative drug companies and is involved in 15 companion diagnostic projects, enhancing its capabilities in core detection technology and data analysis [3] Group 3 - The National Technology Transfer and Transformation Center (Guangdong-Hong Kong-Macao Greater Bay Area) Biopharmaceutical Sub-center has begun construction, selecting 159 quality projects from 664 submissions, covering key areas like cell therapy and AI drug development [3][4] - The "One Island, Multiple Parks" model has been initiated at the Biopharmaceutical Island, promoting resource complementarity and activating regional development [5]